Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma

• PDPK1 is found to be constitutively activated in various types of patient-derived B-cell NHL cells, including mantle cell lymphoma (MCL) which remains to be a highly treatment refractory disease subtype.• PDPK1 plays pivotal roles in cell survival and proliferation of tumor cells of MCL-derive d cell lines.• PDPK1 is suggested to be a potential therapeutic target in MCL.

Source: Experimental Hematology - December 26, 2017 Category: Hematology Authors: Saori Maegawa, Yoshiaki Chinen, Yuji Shimura, Kazuna Tanba, Tomoko Takimoto, Yoshimi Mizuno, Yayoi Matsumura-Kimoto, Saeko Kuwahara-Ota, Taku Tsukamoto, Tsutomu Kobayashi, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda Source Type: research